All publications
GELUCIRE® 4414 for type IV lipid based formulations and their in vitro in vivo performance evaluation
AAPS PharmSci360 – Philadelphia (USA) - 2021
In this study, Gelucire® 44/14 in type IV lipid-based formulation has been evaluated to increase the solubility and in vivo performance of ticagrelor.
Gelucire 48/16® for Type-IV Lipid Based Formulations and Their In Vitro In Vivo Performance Evaluation
AAPS PharmSci360 – San Antonion (USA) - Nov 2019
Understanding The Role Of In Vitro And In Vivo Evaluation Techniques In Determining the Performance of Lipid-Based Formulations
CRS Annual Meeting – Valencia (Spain) - Jul 2019
In this case study using curcuminoids as model drug, the authors show that in vitro lipolysis test is a useful tool to predict in vivo performance
Gelucire 48/16®: A Versatile Non-Ionic Solid Solubilizer for Tablets of Poorly Water-Soluble Drugs
AAPS PharmSci360 – Washington DC (USA) - Nov 2018
A solid dispersion of ticagrelor and Gelucire® 48/16 is prepared to increase drug solubility . The solid dispersion is converted into tablets. The formulated tablets showed improved dissolution rate compared to the market reference.
Bioavailable Curcumin – A Type 4 Lipid Based Drug Delivery System Using Gelucire®48/16 As Solid Solubilizer
CRS Annual Meeting – New York (USA) - Jul 2018
Formulation of a self-emulsifying lipid formulation of curcumin
AAPS Annual Meeting & Exposition – San Diego (USA) - 2014
Characterization of a new self-emulsifying excipient to expand formulation options for poorly soluble drugs: Gelucire® 48/16
AAPS Annual Meeting & Exposition – Chicago (USA) - Oct 2012